Generic Name and Formulations:
Glycerol phenylbutyrate 1.1g/mL (delivers 1.02g/mL of phenylbutyrate); liquid.
Indications for RAVICTI:
Chronic management of patients ≥2 months of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Limitations of use: not for treatment of acute hyperammonemia in patients with UCDs. Safety and efficacy for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.
Adults and Children:
<2 months: contraindicated. Take with food or formula. Administer dose via oral syringe or dosing cup; may give by NG or gastrostomy tube: see full labeling. 2 months to <2yrs: give in 3 or more equally divided doses, rounded to nearest 0.1mL. ≥2yrs: Give in 3 equally divided doses, rounded to nearest 0.5mL; max 17.5mL (19g) daily. Must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements). Phenylbutyrate-naïve: 4.5–11.2mL/m2/day (5–12.4g/m2/day); patients with some residual enzyme activity not adequately controlled with protein restrictions: 4.5mL/m2/day. To determine starting dose in treatment-naïve patients: consider the patient’s residual urea synthetic capacity, dietary protein requirements, and diet adherence. Switching from sodium phenylbutyrate: give dose that contains the same amount of phenylbutyric acid; convert as follows: Total daily dose of Ravicti (mL) = total daily dose of sodium phenylbutyrate tablets (g) X 0.86 or total daily dose of sodium phenylbutyrate powder (g) x 0.81. Moderate-to-severe hepatic impairment: start at the lower end of dosing range. Dose adjustment and monitoring: see full labeling.
Children <2 months of age.
Monitor for signs/symptoms of neurotoxicity; reduce dose if occurs. Pancreatic insufficiency or intestinal malabsorption: closely monitor ammonia levels. Hepatic or renal impairment: monitor closely. Pregnancy. Nursing mothers: not recommended.
Concomitant corticosteroids, valproic acid, or haloperidol may increase plasma ammonia levels; monitor closely. May be potentiated by probenecid. Antagonizes midazolam; monitor. May antagonize CYP3A4 substrates with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine).
Diarrhea, flatulence, headache, nausea, vomiting, decreased appetite, hyperammonemia, dizziness, fatigue, upper abdominal pain, rash. Also peds: neutropenia, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, papule.
Enroll women exposed to Ravicti during pregnancy by calling (855) 823-2595.
Liq (25mL)—1, 4
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally